Carlizumab Plus Sovantinib in Second-line Treatment of Advanced or Metastatic Cholangiocarcinoma
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The incidence of cholangiocarcinoma is high, the radical resection rate is low, the
postoperative recurrence is easy, the prognosis is poor.Gemcitabine combined with cisplatin
(GC) is the standard first-line treatment for patients with advanced biliary carcinoma, and
up to now there is no standard second-line treatment Commend.Carrilizumab was highly
effective in previous studies,Its combined GEMOX protocol has been published in the
"Guidelines for the Diagnosis and Treatment of Gallbladder Cancer (2019 Edition)" and the
"China Clinical Oncology" The Society's (CSCO) Guidelines for the Diagnosis and Treatment of
Biliary alignancies 2020 is recommended for the first-line treatment of advanced biliary
cancers.Solfantinib is targeted at VEGFR1, 2, 3, FGFR1And CSF1R highly selective small
molecule targeted therapy drugs. Data from a preliminary phase 2 clinical trial observed
sofantinib therapy Survival benefits of cholangiocarcinoma patients in China.
Phase:
N/A
Details
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University